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Background: Irritable bowel syndrome (IBS) is a very common gastrointestinal disorder, with 
significant impact on quality of life. Until recently, there has been little evidence-base for 
treating GI symptoms through dietary therapy; clinical treatment is often unsuccessful or 
unsatisfactory. The low-FODMAP diet (LFD) has emerged as a potential therapy for alleviating 
GI symptoms. 
Purpose: The purpose of this project is to evaluate the most current literature to determine the 
effectiveness of the low-FODMAP diet in managing the characteristic symptoms of IBS and to 
potentially identify a subset of the IBS population most likely to benefit from this approach. 
Ideally, this information may be translated into evidence-based and effective clinical treatment. 
Methods:  An electronic search was performed of the Academic Search Complete/EBSCO, 
Google Scholar, and PubMed databases to find related peer-reviewed, full-text articles which 
pertained to the research question. Randomized, controlled trials, descriptive trials, and meta-
analysis studies published between January 2010 and June 2018 were included. Using 
methodology based on the Evidence Analysis process, pertinent data was collected on each study 
and a quality rating was assigned to studies to determine their “weight” in providing evidence for 
the research purpose. 
Results: There were 15 RCTs found and 11 of these RCTs received a positive quality rating. All 
of the positively rated RCTs except for one
 
found benefit to the LFD relative to IBS symptom 
control, although two studies of neutral quality found the LFD to be similar in effectiveness to 
the alternative intervention given to the comparator group.
 
Three observational or non-
randomized studies also found significant benefit(s) to the LFD in improving IBS symptoms, 
3 
 
with two of these studies indicating potential longer-term benefit to the LFD. Abdominal pain, 
bloating, flatulence, and bowel habit status scores were commonly analyzed as variables of 
interest, and most studies found benefit to the LFD for these particular symptoms. Most studies 
did not analyze or include the IBS-C subtype. 
Conclusions: The LFD may be a good approach to use for IBS patients in the alleviation of 
abdominal pain, bloating, flatulence, and other symptoms. There is little evidence to support the 
use of the LFD for IBS-C. Further research should elucidate long-term effects and potential risk 















BACKGROUND & SIGNIFICANCE 
 Irritable Bowel Syndrome (IBS) is a very common gastrointestinal disorder, seen 
often in clinical practice. Prevalence for IBS, based on pooled study populations, is estimated 
around 11.2%, but pooled prevalence estimates vary globally by geographic location (from 1.1% 
to 45%) and also by diagnostic criteria.
1 
 Prevalence is also higher in women than men, and 
higher in persons younger than 50 years, as compared to those older than 50. There are at least 
three, and possibly four, subtypes of IBS – IBS with constipation (IBS-C), IBS with diarrhea 
(IBS-D), and IBS with mixed bowel pattern (IBS-M). Some studies also include an IBS with 
unknown patterns (IBS-U). When considering only three subtypes, a meta-analysis on IBS 
prevalence showed that IBS-D may be the most prevalent and IBS-M the least prevalent.
1
 
However when considering studies that included the fourth subtype (IBS-U), the same meta-
analysis showed the prevalence of each subtype to be evenly distributed amongst the four 
subtypes.  
There is currently no diagnostic biomarker for IBS, and symptoms can overlap with other 
organic gastrointestinal diseases.
2 
It is considered a functional bowel disorder, meaning that 
organic evidence of disease will not be present. As such, it is often, unfortunately, a diagnosis of 
exclusion of organic disease. It is the most commonly diagnosed gastrointestinal disorder, with 
significant impact on quality of life.
3 
IBS is defined by the presence of symptoms such as 
abdominal pain or discomfort, bloating, and altered bowel patterns, in the absence of any organic 
disease. The most recently revised Rome IV criteria should be utilized for diagnosis, which 
requires assessing the frequency of abdominal pain in association with changes in stool 
frequency and form.
2
 Subtyping can then be assessed utilizing the Bristol Stool Form Scale and 
assessment of frequency of stool types. In most patients, IBS presents as a chronic relapsing 





There are multiple comorbidities associated with IBS, ranging from somatic pain 
syndromes, other gastrointestinal disease, and psychiatric disorders, perhaps pointing to a shared 
pathogenesis.
3
 Pathophysiology of the disease is complex and multifactorial, possibly indicating 
IBS may encompass a variety of distinct diseases that share similar symptoms. Factors 
contributing to IBS pathophysiology and symptoms may include altered pain perception and/or 
brain-gut interaction, dysbiosis, increased intestinal permeability, increased gut mucosal immune 
activation, and heightened visceral sensitivity.
3 
 
Within the clinical realm, diet is an undisputed factor to consider when treating IBS, and 
patients often associate their IBS symptoms with eating a meal.
3
 Foods can trigger the functional 
bowel symptoms associated with IBS. However, there are several reasons why IBS can be 
difficult to treat with diet. Firstly, IBS is multi-faceted and symptoms may be triggered by 
contributors that are not diet-related (i.e., life stressors, antibiotics, infection).
 
There is a well-
known psychological component to IBS dynamics, linking psychological state to symptom 
fluctuation.
3
 IBS may also be difficult to treat nutritionally because symptoms and/or dietary 
triggers may be very different depending on the subtype of IBS that is present. Current research 
is unclear as to the major distinctions for dietary treatment of IBS-C vs. IBS-D, however, some 
studies have found differences in symptom response to dietary management between these 
subtypes.
4 
In addition, standard or “traditional” diet approaches are often not sufficient to resolve 
symptoms. It is not uncommon in clinical practice to see patients who have implemented 
“traditional” diet advice and yet still struggle with unresolved symptoms. Finally, depending on 
the type of diet therapy offered, recommended changes may be complicated and/or difficult for 
the patient to implement, especially long-term.  
6 
 
There is inconsistency within the clinical realm as to what type of dietary therapy is 
provided for IBS. In general, there is little evidence concerning the underlying mechanisms by 
which food triggers functional bowel symptoms, which makes it difficult to develop diagnostic 
tests to detect certain food triggers.
5
 Historically, there has been little evidence for effectiveness 
of dietary interventions on IBS symptoms. A trial-and-error approach is often taken within 
clinical practice, which could be considered an ineffective or inefficient approach, not to mention 
frustrating for patients seeking symptom relief. Traditional dietary advice, which may focus on 
timing of meals and certain food-related triggers like caffeine and alcohol, (such as that laid out 
in the United Kingdom’s National Institute for Health and Care Excellence or “NICE” 
guidelines
6
) may be commonly offered; however emphasis and scope can be very different from 
clinician to clinician, likely contributing to patient frustration. Advice offered in the primary care 
setting may be often very basic, given the usual limited timeframe for patient education.
  
Because 
of the nature and mechanisms of IBS as currently understood, there is likely a need for 
recommendations to be tailored to the individual’s situation and symptoms. 
Only within recent years, published literature has quickly multiplied in utilizing a diet 
low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols—the low-
FODMAP diet—to treat IBS symptoms. In fact, over the last 5-10 years, the low-FODMAP diet 
has become one of the most well-studied diets for functional bowel disorders, with numerous 
randomized controlled trials conducted in several geographic locations worldwide.
7   
The low-
FODMAP diet involves the restriction of 4 groups of short-chain fermentable carbohydrates 
which include the following: 1) oligosaccharides, fructans, and galacto-oligosaccharides—found 
in wheat and rye products, legumes, nuts, artichokes, onions and garlic; 2) the disaccharide 
lactose—found in milk products; 3) the monosaccharide fructose—found in fruits such as apples, 
7 
 
pears, watermelon, mango, as well as honey and some vegetables; and 4) polyols like mannitol 
and sorbitol--found in apples, pears, stone fruits, cauliflower, and mushrooms—as well as 
artificial sweeteners like xylitol.
8 
Restriction of individual carbohydrates (i.e., lactose or fructose) for the treatment of IBS 
symptoms is not a novel concept and has been commonly used for years; however, the collective 
and broader restriction of all of the aforementioned short-chain carbohydrates is what has been 
studied more recently.
5 
Elimination or restriction of these carbohydrates is based on the idea that 
many of these carbohydrates enter the colon because of a lack of hydrolysis (fructans and 
galacto-oligosaccharides), incomplete hydrolysis (lactose), or incomplete absorption (fructose 
and polyols). These incompletely digested and highly fermentable carbohydrates are then 
potentially exacerbating IBS symptoms by increasing small intestinal water volume (i.e., osmotic 
effect of fructose and polyols
8
), small intestinal motility and colonic gas production.
5 
Through 
reducing gas production and water, luminal distention may be limited, potentially reducing 
symptoms like bloating, pain, and excessive gas. Additive and dose-dependent effects of these 
carbohydrates may then be plausible.
5 
Interestingly, there is evidence that it is not technically 
malabsorption, greater gas production, or visceral distention that drives IBS symptoms, but it is 
colonic hypersensitivity to distention that results in carbohydrate-related symptoms in these 
patients.
9-10 
 The low-FODMAP diet begins as an elimination diet but is not intended to remain 
extremely restrictive. Seen as a whole, the diet is not a lifelong diet, but rather an approach to 
drastically drop FODMAP intake to a level at which they do not induce gastrointestinal 
symptoms followed by careful reintroduction and personalization of the diet.
2 
 Ideally, the diet 
implementation is executed via three important stages/clinical visits: 1) an initial clinical visit for 
8 
 
assessment, careful explanation and counseling on FODMAP restriction, 2) a second visit for re-
assessment of diet/symptoms and counseling on FODMAP reintroduction to identify triggers, 
and 3) long-term personalization whereby a less restrictive diet is consumed. The restrictive 
phase typically lasts around 4 weeks but the process of re-challenge and personalization may 
require a lengthier commitment to the approach. The important aim in the multiple steps outlined 























 Based on the clinical picture of IBS presented thus far and the recent and rapidly 
accumulating works concerning low-FODMAP dietary therapy, it is necessary to review current 
research for the most updated evidence on the effectiveness of this approach. The purpose of this 
project is to evaluate the most current literature to determine the effectiveness of the low-
FODMAP diet in managing the characteristic symptoms of IBS and to potentially identify a 
subset of the IBS population that is most likely to benefit from this approach. This information 
will not only provide dietetic professionals with the most updated evidence of this potential 
nutrition therapy, but may also serve to identify a critical learning need for those nutrition 
providers who give services to patients affected by IBS. Ideally, the information gained by this 
review will also serve to provide more consistency amongst healthcare providers and will 




 The proposed literature review will discuss: 
a) Low-FODMAP dietary interventions within the literature. 
b) Control and comparator groups utilized with the low-FODMAP diet. 
c) Tools utilized to measure IBS symptoms. 
d) Key trends in symptom response to the low-FODMAP approach. 
e) Individual symptom response to the low-FODMAP approach. 




 The literature utilized in this review was gathered using an electronic search of the 
Academic Search Complete/EBSCO, Google Scholar, and PubMed databases to find related 
peer-reviewed, full-text articles. Keywords for the search included IBS, irritable bowel 
syndrome, and functional bowel/gut, combined with diet, food, nutrition, meal, lifestyle and/or 
treatment. Titles and abstracts were reviewed to determine applicability to the research question. 
Preference was given for including experimental studies with randomized, controlled designs to 
best contribute to the development of evidence-based guidelines; however, descriptive studies 
were also included if results or methods are applicable to the research question. Meta-analyses 
pertaining to the research question were included. Reference lists of included studies were cross-
referenced for other studies of potential relevance. Only recent articles published between 
January 2010 and June 2018 were considered for this review. The Evidence Analysis Manual’s 
“Search Plan & Results Template” was utilized to organize articles to be included or excluded 
from the review.  Inclusion and exclusion criteria for articles are listed in Table 1 below. 
 
Table 1: Inclusion vs. Exclusion Criteria 
Inclusion Criteria` Exclusion Criteria 
Full-text articles Articles with only abstract available 
Peer-reviewed  Secondary reports (other than meta-analysis) 
Primary research or Meta-analysis Studies performed on children or patients <18 
years of age 
Published between Jan 2010 and June 2018 Studies performed on patients without clearly 
diagnosed IBS 
Studies done on adults (age 18+) Studies which did not formally assess IBS 
symptom response after low-FODMAP 
intervention 
Studies performed on patients 
formally/clinically diagnosed with IBS (i.e., 
Rome criteria) 
 
Formally validated or clear method/tool 
utilized to measure IBS symptoms 
 





 A total of 26 studies, 22 primary reports and 4 meta-analyses, were included for review 
and were critically appraised using methodology based on the Evidence Analysis process. The 
Evidence Analysis Library’s (EAL) “Worksheet Template” (see Appendix A) was utilized to 
collect pertinent data on each study. Once this data was extracted from each study, the EAL’s 
“Quality Criteria Checklist” for either Primary Research or Review Articles (whichever was 
appropriate) was utilized to assign a quality rating to each study (see Appendices B and C). 
Studies were given a quality rating of positive, neutral, or negative, based on the score they 
obtained from the quality criteria checklist. Of the 26 studies included in the critical appraisal 
process, 22 of them (18 primary reports and 4 meta-analysis studies) obtained either a positive or 
netural score, and thus were considered in determining the “weight” of evidence for the research 
question. The 4 studies that were assigned a negative quality rating were not considered in 
weighing the evidence; thus these studies were not summarized in the study “Overview Table” 













 From the literature search as described previously, there were 15 original research articles 
identified describing randomized controlled trials (RCTs) which were relevant to the research 
question.
12-26
 Of these RCTs, the majority of them (11 out of 15 studies) received a positive 
quality rating
12-22
 and the remaining (4 out of 15) received a neutral quality rating.
23-26
 All of the 
positively rated RCTs except for one
15
 found some benefit to the low-FODMAP diet (LFD) in 
regards to IBS symptom control, although two studies of neutral quality found the LFD to be 
similar in effectiveness to the alternative intervention given to the comparator group.
25-26 
In 
addition to the RCTs, there were two observational studies
27-28
 and one non-randomized 
controlled trial
29
 that were identified as relevant and rated of neutral quality. These three studies 
also found significant benefit(s) to the LFD in improving IBS symptoms, with the two 
observational studies indicating potential longer-term benefit to the LFD.  
Interventions 
 The interventions utilized for a LFD in these studies primarily consisted of one-on-one 
verbal and written diet education. A trained dietitian or group of dietitians typically provided all 
dietary counseling, with 1-3 sessions of 30-60 minutes each. It is important to note that most of 
these clinical studies did not include the FODMAP reintroduction stage of the diet; rather, the 
intervention period only included the elimination phase of the diet. Thus there is little evidence 
available of the “long-term” effectiveness of the LFD, which ideally should include the three 
stages of 1) initial elimination, 2) reintroduction, and 3) personalization (as discussed 
previously).
11
 However, there were three “long-term” studies identified which did clearly include 
FODMAP reintroduction in their methods. 
21, 27-28  
These studies analyzed longer-term data on 
13 
 
IBS symptoms in response to LFD education, with follow-up data ranging from 6-18 months 
after study initiation.    
 Three of the studies selected for review provided low-FODMAP food for dietary 
intervention – all three were randomized, controlled, cross-over trials.
16,20,24  
Both Halmos et. al
16 
and Ong et. al
24 
provided subjects with all daily food; the former provided food for 21 days of 
treatment and the latter provided food for a short two-day intervention. Laatikainen et. al
20 
only 
provided subjects with a certain number of bread slices (low-FODMAP vs. regular rye bread) 
and allowed a habitual diet to continue. The studies providing subjects with all food certainly 
present a strength for dietary control and an opportunity for examining the specific role of 
FODMAPs, especially as the intervention and control diets seemed to be well-matched for 
various potential nutrient confounders. However, as Halmos et. al
16 
points out, this type of study 
design is not representative of reality and has limited applicability to real-life clinical treatment. 
Further, these studies did not or could not control for gluten intake, which could be a 
confounding dietary factor when studying symptomatology of IBS. Interestingly, when wheat 
intake is lowered, both fructans (a FODMAP) and gluten are reduced, making it more difficult to 
ascertain the true cause of symptom relief.
4  
Control/Comparator Groups 
 The low-FODMAP diet has been compared to many different alternative intervention 
diets or “control” diets. In fact, the RCTs examined are significantly heterogeneous in their 
methodology, in large part due to the comparator diet which is used to contrast the LFD. Four 
studies
13-15,29
 compared the LFD to what is considered “traditional” dietary therapy based on 
NICE guidelines; although one of these studies modified NICE guidelines so that no FODMAP 
14 
 
food was excluded in their traditional diet group.
14 
It is important to note that there is some 
potential overlap between NICE guidelines and LFD therapy, i.e., there are a few FODMAP 
foods restricted in the NICE guidelines, although not nearly as restrictive as the LFD. Three 
studies
18,21,25 
compared the LFD to a habitual diet, or a non-intervention control group (no 
placebo control). One study
16
 (previously mentioned) compared the LFD to a typical Australian 
diet but provided placebo control by providing blinded subjects with all daily food during the 
study period (however, the authors note they may have over-estimated some FODMAP content 
in the provided typical diet). Three studies compared the LFD to a high-FODMAP diet, with one 
providing all food for a short time-period,
24
 another providing high-FODMAP dietary advice,
12 
and another comparing high intake of one particular FODMAP (fructo-oligosaccharides 
supplement vs. placebo supplement) with the LFD.
22
 One study compared the LFD to a specific 
carbohydrate diet,
17 
one compared effectiveness to a yoga-based intervention,
26 
one compared to 
a probiotic supplement (in addition to non-intervention group),
25
 one compared low-FODMAP 
vs. regular rye bread in a habitual diet,
20
 and one compared the LFD to a “sham” diet which was 




 performed a systematic review (2016) using nine RCTs which 
examined the role of the LFD on IBS symptoms. This review notes that choosing a control group 
for this type of research is very challenging; there are truly no established evidence-based 
treatment options for IBS with which to compare to the LFD. The review by Krogsgaard et. al 
criticizes the control groups in most studies do not allow discrimination of the true effect of the 
diet, and control groups utilized in future research should be chosen based on proven efficacy 
(and/or role as standard of care); true placebo control is also essential for this type of research. 





Interestingly, there have been at least two RCTs published in the last two years that have 
offered placebo-control and were able to show some significant benefits for the LFD 
approach.
19,22  
Tools for Measuring Symptom Effect 
 Within the research, there have been many tools utilized to measure IBS symptom change 
in response to the LFD and other interventions. All of the tools utilized are self-rated scales for 
the patient to complete. Perhaps the most popular is the formally validated symptom 
questionnaire, the IBS-Symptom Severity Score or IBS-SSS. This score can provide a measure 
of overall symptom severity, and consists of five questions regarding abdominal pain severity, 
abdominal pain frequency, abdominal bloating, bowel habit dissatisfaction and interference with 
quality of life on a visual analogue scale (VAS) from 0-100.
32 
There were 9 RCTs examined that 
utilized the IBS-SSS scale to measure symptom response, although it was not always utilized as 
the primary endpoint.
12-13,15,19-22,25-26
 Other VAS scales have also been used to measure various 
GI symptoms (0-10mm or 0-100mm scales).
16-17,20,22
  Another scale validated in the IBS 
population to measure symptom response is the GI Symptom Rating Scale or GISRS.
18
 This 
scale has been utilized to measure various GI symptoms using a 4-point scale.
18-19,27  
Various 
non-validated Likert scales have been used to measure a number of IBS-related symptoms or 
symptom changes retrospectively.
24,28-29 
In addition to measuring individual/total symptoms or 
the change in symptoms, other important endpoints have been used to examine the effects of the 
LFD, including a “global symptom question” (yes/no question regarding being adequately 
controlled),
18-19,22,27 
an “adequate relief” question,
14 
bowel habit status scores (using Bristol Stool 
Chart or King’s Stool Chart),
13-16,18-19,27 





Key Trends in Symptom Response 
 Most of the RCTs examined for this review did report positive effects of the LFD on IBS 
symptoms.  As discussed, reduction in IBS-SSS score(s) was one of the primary or secondary 
outcomes of most of the RCTs reviewed. One of the largest RCTs (n=101) by Zahedi et. al
13
 
compared LFD education to traditional dietary advice (similar to NICE guidelines) and found 
that although both interventions reduced IBS-SSS scores and improved bowel habit status scores 
(stool consistency and frequency), the LFD  produced a greater reduction in all of these 
measurements. In this Iranian population which only included IBS-D patients, all of the 
individual item symptom scores (included on the IBS-SSS) were significantly decreased in the 
LFD group vs. the traditional diet group. Another study with a larger sample size (n=104 in ITT 
analysis) by Staudacher et. al
19 
 measured IBS-SSS scores and compared the LFD with a placebo 
sham diet. These authors reported not only were total symptoms scores reduced in the LFD 
group, but 73% of patients reported a global clinical response or made what is referred to as 
“clinically meaningful improvement” based on IBS-SSS (reduction in total score of >50) vs. 
42% in the sham diet group. This study examined all subtypes of IBS except IBS-C (and 
majority of subjects had IBS-D). Another smaller study by Harvie et. al
21
 found significantly 
lower IBS-SSS scores and increased IBS-QOL scores for a LFD group (dietary education) after 
three months with sustained reductions at 6 months; however, this study compared the LFD in all 
IBS sybtypes to a parallel, non-intervention control group where placebo effect was not 
mitigated. In addition, an interesting smaller, double-blinded placebo-controlled crossover trial 
(n=20) by Hustoft et. al
22 
examined subjects educated to a LFD diet and then supplemented with 
either an average daily amount of FODMAPs (via a fructo-oligosaccharide pill) or placebo. Not 
only did all participants see a significant drop in IBS-SSS score after 3 weeks on the LFD, but 
17 
 
symptoms were significantly greater in the FODMAP group vs. the placebo after the double-
blinded supplement was given. A “global” question regarding symptom relief was also an 
outcome of this study, and 80% of participants reported symptom relief in response to placebo 
(LFD) vs. 30% to the FODMAP-supplemented group. 
 There is some evidence indicating the LFD has an advantage over other potential 
nutrition therapies. There were four studies identified which compared the LFD to other diet 
therapies, three of which compared LFD education to NICE guidelines
13-14,29
 and one of which 
compared LFD education to a Specific Carbohydrate Diet (SCD).
17
 One RCT and one non-
randomized controlled trial
 
found significant advantages for the LFD as compared to NICE 
guidelines.
13,29 
Another study by Eswaran et. al
14
 compared modified NICE instructions (which 
did not exclude any high FODMAP foods) with LFD education and found no difference in rates 
of “adequate relief” for IBS-D symptoms, but significantly greater reductions in abdominal pain, 
bloating, stool consistency, frequency and urgency with the LFD (as measured by numerical 
rating scale). Another study used a VAS scale and found significant reductions in abdominal 
pain and bloating in IBS patients after LFD education, as compared to no significant benefit with 
the use of the SCD.
17
 
 On the other hand, there is certainly some evidence that although the LFD is effective, it 
is similar in effectiveness to other interventions. A single-blinded RCT performed with Swedish 
subjects (n=67) compared groups who had been educated to the LFD vs. educated to traditional 
dietary advice (NICE guidelines).
15
 Although IBS-SSS scores suggest symptom severity was 
reduced in both groups, changes relative to baseline did not actually differ between groups and 
approximately 50% of the subjects in both groups responded well to treatment. It is interesting to 
note that the group given traditional dietary advice also excluded some FODMAP-containing 
18 
 
foods, as per NICE guidelines. Another relatively large study (n=108) by Pedersen et. al
25 
allocated patients to one of three groups: 1) LFD education (with some reintroduction 
education); 2) probiotic supplementation with habitual diet; or 3) control group with access to 
web-based general IBS education. Again, each of the 3 groups had a significant reduction of 
IBS-SSS scores; however, the probiotic and the LFD group both had significant reductions 
compared to control (although LFD group appeared to have greater advantage than the probiotic 
group when comparing changes in IBS-SSS over the 6-week study period). Schumann et. al
26
 
also found similar reductions in IBS-SSS score when comparing LFD education to yoga therapy 
over a 12-week intervention period. As these studies suggest, placebo response is very obviously 
present in this type of research and is an essential factor to consider when determining the true 
effectiveness of this diet. 
 There were two studies examined which compared the use of a LFD with a high-
FODMAP diet (above normal average intake). As Krosgaard et. al
30 
notes, this comparison is not 
clinically relevant, as the control arm does not serve as a placebo or as a potential treatment 
option. However, these types of studies serve to further understanding on the effects of 
FODMAPs in IBS patients. McIntosh et. al
12
 reported a significant decrease in symptom scores 
(IBS-SSS) in patients educated to the LFD and a non-significant increase in symptoms in IBS 
patients educated to a high-FODMAP diet. Interestingly, these authors observed a positive 
correlation between dietary FODMAPs and increasing GI symptoms. Another study used a 
randomized crossover trial with 15 healthy subjects and 15 IBS patients to compare a LFD to a 
high-FODMAP diet, with all food provided for a 2-day period.
24
 Using a 4-point Likert scale, 
these authors found a high-FODMAP diet significantly worsened symptoms for both patient 
populations, although the healthy population had worsened symptoms only due to increased 
19 
 
flatus. In addition to lower GI symptoms, IBS patients also reported increased upper GI 
symptoms and lethargy in response to this short-trial of high-FODMAP foods. These trials 
elucidate some of the potential mechanism behind FODMAP foods and their potential for 
symptom induction in IBS patients. 
Individual Symptom Response 
 Within the clinical realm, in addition to general symptom response, it is arguably most 
helpful to use the literature to identify those specific symptoms which a LFD is most likely to 
alleviate. This helps clinicians target those IBS patients who would potentially have the greatest 
benefit to this approach. Although there are differences between studies in regards to specific 
symptoms measured, most studies evaluating the LFD assess at least some measure of individual 
GI symptoms. Many studies measure individual symptoms such as those included in the IBS-
SSS (abdomen pain intensity/frequency, distention, dissatisfaction of bowel habit, and 
interference on life in general) and lower GI symptoms were most commonly assessed. Eswaran 
et. al
14
 and several others
12-13,16,18-19,27-29 
have demonstrated the benefit of a LFD on both 
abdominal pain and bloating, in particular. Flatulence, although not as frequently measured, also 
appears to be reduced with a LFD.
16,18-20, 27-29  
Several studies have investigated bowel habit 
status scores and found benefit in favor of the LFD, with five of these studies reporting benefit to 
stool frequency
13-14, 16,18,27 
 and six improving stool consistency.
13-14,16, 18-19,27 
One other study did 
find benefit to the LFD in reduction of stool frequency but results were not significantly better 
than the comparison group (traditional IBS/NICE dietary guidelines).
15
 It is also essential to note 
that most of these studies enrolled primarily IBS-D patients and many did not analyze results by 
IBS subtype. One cited study which examined bowel habit status scores found the improvement 





Other symptoms examined and perhaps less common within the literature include upper 
GI symptoms (nausea/vomiting, belching/gas), borborygmi (stomach rumbling), urgency, 
fatigue/tiredness, and IBS-related quality of life. Staudacher et. al
18 
 and Laatikainen et. al
20
 
reported reductions in borborygmi with either a LFD vs. habitual diet and low-FODMAP bread 
vs. regular rye bread, respectively. The former also reported benefit to the LFD for stool 
urgency, as did another RCT comparing LFD to modified NICE guidelines.
14 
 At least two 
studies have examined upper GI symptoms relative to FODMAPs; one found significant 
reduction of belching/gas and nausea/vomiting scores with a LFD, with a subsequent increase in 
these scores with supplementation of a certain FODMAP (FOS).
22
 Another study also 
demonstrated increased upper GI symptoms (heartburn and nausea) with a high-FODMAP diet 
as compared to a low-FODMAP diet, whereas healthy controls did not have this response to 
increased FODMAPs.
24
 In this study IBS patients also reported increased tiredness when fed a 
high-FODMAP diet. Finally, IBS-related quality of life was reported in response to low-
FODMAP interventions in several of the studies via the IBS-QOL assessment. Four 
studies
19,21,23,25
 utilizing IBS-QOL as an outcome observed increased quality of life after low-
FODMAP interventions. One was only able to demonstrate improvement in a few individual 
areas of the QOL assessment
19
 and another could only show improved QOL in the IBS-D 
subtype.
25
 Another study failed to show any significant difference in QOL, although this study 
only intervened via provision of low-FODMAP vs. regular bread and did not target a full-diet 
adjustment.
20 
 There were four meta-analyses identified, each with its own methodology to analyze a 
LFD approach in managing IBS symptoms.
32-35
 The earliest meta-analysis by Marsh et. al
33
 
analyzed IBS-SSS and IBS-QOL scores in a total of 22 studies (6 RCTs and 16 non-randomized 
21 
 
interventions) and showed a positive association between the LFD and significant decrease in 
IBS-SSS score. This study reported abdominal pain and bloating were the symptoms which 
showed the most improvement in the RCTs and bloating, flatulence, pain, diarrhea, nausea and 
constipation (respectively) showed the most improvement in non-randomized interventions. A 
study by Varju et. al
32
 also analyzed IBS-SSS scores, but in only controlled and uncontrolled 
studies which utilized LFD vs. a control group consisting of a standard IBS diet. This study 
found a LFD diet to be superior to a standard IBS diet in improving IBS-SSS score; however, it 
should be noted that standard IBS diet groups were very heterogeneous, with only two out of ten 
studies detailing exact food contents. Another meta-analysis by Altobelli et. al
35
 examined 6 
RCTs and 6 cohort studies, aiming to examine a LFD vs. traditional IBS diet, a LFD vs. 
medium- or high-FODMAP diet, and a LFD without comparator in cohort studies. This analysis 
reported LFD significantly reduced pain and bloating in all types of studies, with the additional 
benefit of improvements in stool frequency in the LFD v. traditional IBS diet studies (but no 
improvement in stool consistency). Finally, the most recent of meta-analyses by Schumann et. 
al
34
 looked only at 9 RCTs (n=561 patients) which compared LFD to other diets and included a 
variety of patient-rated scales. Again, group differences were found for the LFD as compared to 
any control for GI symptoms and abdominal pain, and secondary outcome analysis found short-
term improvements in quality of life. This study noted improvements were mainly seen with 
IBS-D patients. Authors of these meta-analysis studies note limitations to the current research, 
including inadequate blinding for the outcome assessment,
34-35
 a general high risk for 
performance bias,
34 
lack of adequate information on IBS subtypes,
32-34
 limited ability to 




lack of control of dietary 
adherence,
33-34





IBS Subtype Analysis 
 There is currently a lack of evidence for the LFD in treating all IBS subtypes. In 
particular, the constipation-predominant IBS subtype has not been adequately studied for more 
conclusive results. There were six RCTs within this literature review that specifically excluded 
IBS-C subtypes
13-14,18-20,22
 and two of these studies only included patients with IBS-D.
13-14 
Several studies either had too few IBS-C patients to perform subgroup analysis or simply did not 
perform/publish a subgroup analysis,
12,17,21,24,27-29
  although de Roest et. al
28
 did report long-term 
improvement in constipation as well as other symptoms. Bohn et. al
15
 included some analysis of 
subtypes in their RCT, but were unable to demonstrate a difference between IBS subtypes; the 
authors admit the trial was not powered to detect subgroup differences. Pedersen et. al
25
 
demonstrated benefits in symptom reduction in IBS-D and IBS-M patients, but no benefits were 
found for IBS-C patients. Halmos et. al
16
 found similar beneficial results in pain, bloating, 
flatulence and satisfaction with stool consistency in both IBS-C and IBS-D subtypes, but only 
IBS-D subtypes had improvements in fecal frequency. Collectively, literature concerning the 
effectiveness of the LFD in constipation-predominant IBS appears sparse and inconclusive. It 
has been argued that as pain, bloating and flatulence may be found in all subtypes, it is possible 
that the LFD may still be helpful for IBS-C patients.
15
 Although the LFD could lessen the 
discomfort often present in association with constipation, reduction of FODMAPs could also 
potentially reduce one’s fiber intake, aggravating transit issues and contradicting benefit of the 
LFD.
36 
Interestingly, a long-term follow-up study found a greater proportion of patients on an 
“adapted FODMAP” diet (who had already gone through the reintroduction phase of the diet) 
met fiber requirements than those who returned to a “habitual” diet.
27 
However, more longer 
23 
 
term studies are needed to assess the adequacy of fiber and other nutrients after all phases of the 
LFD have been implemented. 
  
Limitations 
 There were several important limitations identified in the current body of research for the 
LFD as it relates to IBS symptom control. Firstly, results cannot be generalized to all 
populations. As discussed in the previous section, these results were seen for the IBS population, 
and more specifically, mostly for those without the constipation-predominant subtype (diarrhea-
predominant and mixed subtypes are more likely to benefit from this approach). In addition, the 















 Results may then not be generalized to all 
cultures or geographic locations. It is also possible that these results do not apply the same to 
males. A recent meta-analysis by Schumann et. al
34 
indicated RCTs were 67-86% female. 
However, related studies may simply reflect a clinical reality, as prevalence of IBS has been 
estimated at 14% of females vs. 9% of males.
1 
Finally, as with all dietary therapies, results are 
more likely to be seen when subjects have the physical and mental capability of adhering to the 
diet; thus results cannot be expected within the general population or within any socioeconomic 
status. Not surprisingly, a long-term observational study by de Roest et. al.
28
 reported a 
significant positive correlation between adherence to the LFD and improvement in IBS 
symptoms. Any elimination or restrictive diet such as the LFD is unlikely to be helpful and could 
be potentially harmful if patients have obvious barriers to adherence (i.e., financial, cognitive 
limits, etc.). As almost all of the studies in this review incorporated dietitian-led education, there 
24 
 
is little to no evidence that the LFD should be provided by anyone but a trained dietitian who 
would presumably be able to adequately assess for the appropriateness of the approach. 
 Many of the studies within this review lack adequate blinding and generally suffer from 
risk of performance bias. Most of the RCTs attempted to blind participants to the intervention 
assignment, however, many did not formally assess the adequacy of the blinding. It may be 
likely that some patients were able to deduce the nature of the diet that they were on; this may 
become more likely as the LFD approach continues to gain more popularity. This risk of bias 
which intervenes with a formal LFD education could artificially inflate positive results, 
especially as placebo effect is so strong within this area of study. As a systematic review by 
Krogsgaard et. al
30
 suggests, future studies should be assessing the adequacy of the blinding on 
the side of the participant. In addition, although there were two studies which afforded a design 
that could be double-blinded,
20,22
  it is not realistic to blind the educator who gives the LFD 
education; thus, those studies which provided more clinically relevant situations (LFD education 
by a dietitian) may risk bias on the part of those giving the intervention. This risk of bias is likely 
unavoidable in these types of studies. 
 Another potential limitation of these studies that is worth noting is a general lack of 
control for dietary adherence. Of those studies that utilized LFD education and assessed 
nutrient/FODMAP intake,
14-15,18-19, 21
 there was significantly less FODMAP intake in the LFD 
intervention group (i.e., intake was as expected after dietary intervention). However, these results 
cannot necessarily be generalized across studies. Typically, adherence was measured via a food 
diary implemented in the last several days of the intervention period; thus, strict control was not 
feasible. A meta-analysis published in 2016 by Marsh et. al
33
 indicated a lack of studies 
providing adherence figures and quantities of FODMAPs ingested. A meta-analysis published in 
25 
 
2017 by Varju et. al
32
 found similar issues with only 2 out of 10 studies detailing exact food 
contents. In general, future studies should include feasible methods of assessing dietary 
adherence, although strict control of dietary intake is challenging and/or unfeasible for research 
in the “realistic” clinical education setting.  
 Although not necessarily a limitation, it is important to note the variable study duration 
within these studies. There were few studies that looked at longer-term effects of the LFD, and 
most did not include a FODMAP reintroduction period. Most examined only the initial low-
FODMAP phase, with widely different study durations. It appears the LFD may be effective for 
abdominal pain in as little as 2 days,
24
 but study durations for the initial low-FODMAP phase 
lasted as long as three months.
21 
One RCT found greatest symptom control was established about 
seven days after implementation of the LFD.
16 
The meta-analysis by Marsh et. al
33
 found the 
widely variable study duration may potentially act as a confounder of results, as results may be 
then more diversified. It is also possible that changes to the gut microbiota may play a role in 
symptom improvement and it has been suggested that these changes may take up to eight weeks 
to occur.
18 
Long-term studies are greatly needed in this area of research, as this will help 
determine the true effectiveness and clinical meaning for the LFD. 
 Finally, it is evident from current research that an important limitation to the use of this 
diet is potentially unknown long-term side effects. Potential side effects of concern include 
nutrient inadequacies and detrimental gastrointestinal microbiota alterations. One longer-term 
study (6 months) found initial decreases in fiber intake but a subsequent increase after FODMAP 
reintroduction.
21
 An observational study suggests a LFD can be nutritionally adequate up to 18 
months after the dietary education, with no evidence of harm in the low-FODMAP group which 
maintained a selectively limited FODMAP diet.
27
 Overall, there is a need for more research to 
26 
 
determine possible nutrient inadequacies long-term. Although there is evidence that the initial 
low-FODMAP phase can alter the microbiome in a potentially unfavorable way,
12, 18-19, 22 
none of 
the studies were able to adequately assess long-term changes (after FODMAP reintroduction) to 
the microbiome. These long-term effects are a necessary research area and currently, they are 
likely the most important determinants and/or potential barriers to the clinical use of a LFD.  
Discussion/Conclusion 
 The low-FODMAP diet has been a very popular research area in recent years, with 
encouraging results for those that suffer from symptoms of IBS. As IBS is such a common 
disorder with considerable clinical cost, effective treatments are no doubt going to be met with 
enthusiasm. A dietary approach is also considered a more acceptable approach and may be more 
welcome in current US culture than the pharmacological approach. This literature review has 
identified a considerable number of RCTs and some observational studies which have 
investigated the effect of the LFD on GI symptoms. Based on the articles included in this review, 
it appears that the LFD has significant benefits in reducing GI symptoms that accompany IBS, 
particularly abdominal pain, bloating, and flatulence. Bowel habit status scores (stool frequency 
and consistency) also seem to improve with the LFD, although this effect might not apply to the 
IBS-C subtype. It is possible that it has benefit in the alleviation of other upper GI symptoms and 
non-GI symptoms; however, more research needs to be performed in these areas. Quality of life 
also seems to improve for IBS patients on a LFD. In general, the evidence base is only strong for 
utilizing this approach in the IBS-D and IBS-M population. It is possible that patients with the 
IBS-C subtype may still have benefit, particularly with symptoms such as pain and bloating; 
however, there is not enough evidence for a definite conclusion.  
27 
 
 There are certainly unknowns for the LFD approach which need further elucidation. It 
does appear that this approach is more effective than placebo or a standard IBS dietary therapy; 
however, more research should be done. Ideally, RCTs should be well-designed, with placebo 
control, adequate blinding of the participant and investigator, and adequate assessment of dietary 
intake, dietary adherence, and other possible confounders (medications/supplements,etc.). 
Admittedly, designing a study without these weaknesses is challenging and likely costly. 
Additional research should further analyze effects on all subtypes of IBS (particularly IBS-C) 
and on more diverse populations. Arguably, the most important need for further research lies in 
the long-term effects of the LFD, which would encompass all stages of the diet. The beginning 
stages of the long-term research do not indicate nutrient inadequacies, but point towards the 
potential for alteration of the gut microbiome. These areas should be investigated further. 
 In conclusion, the LFD may be a good approach to use for IBS patients in the alleviation 
of abdominal pain, bloating, flatulence, and other symptoms. Patients without IBS-C and with 
applicable GI complaints should likely be targeted for potential use of this dietary therapy. 
Further research should elucidate long-term effects and potential risk vs. benefit analysis in 
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 Neutral – indicates that the report is neither exceptionally strong nor exceptionally 
week 
Select a rating from the                    
drop-down menu  
Relevance Questions 
1. Will the answer if true, have a direct bearing on the health of patients? Select a Rating 
2. Is the outcome or topic something that patients/clients/population groups would care 
about? 
Select a Rating 
3. Is the problem addressed in the review one that is relevant to dietetics practice?  Select a Rating 
4. Will the information, if true, require a change in practice? Select a Rating 
If the answers to all of the above relevance questions are “Yes,” the report is eligible for designation with a 
plus (+) on the Evidence Quality Worksheet, depending on answers to the following validity questions. 
Validity Questions 
1. Was the question for the review clearly focused and appropriate? Select a Rating 
2. Was the search strategy used to locate relevant studies comprehensive? Were the 
databases searched and the search terms used described? 
Select a Rating 
3. Were explicit methods used to select studies to include in the review? Were 
inclusion/exclusion criteria specified and appropriate? Were selection methods 
unbiased? 
Select a Rating 
4. Was there an appraisal of the quality and validity of studies included in the review? 
Were appraisal methods specified, appropriate, and reproducible? 
Select a Rating 
5. Were specific treatments/interventions/exposures described? Were treatments similar 
enough to be combined?  
Select a Rating 
6. Was the outcome of interest clearly indicated? Were other potential harms and 
benefits considered?  
Select a Rating 
7. Were processes for data abstraction, synthesis, and analysis described? Were they 
applied consistently across studies and groups? Was there appropriate use of 
qualitative and/or quantitative synthesis? Was variation in findings among studies 
analyzed? Were heterogeneity issued considered? If data from studies were 
aggregated for meta-analysis, was the procedure described? 
Select a Rating 
8. Are the results clearly presented in narrative and/or quantitative terms? If summary 
statistics are used, are levels of significance and/or confidence intervals included? 
Select a Rating 
9. Are conclusions supported by results with biases and limitations taken into 
consideration? Are limitations of the review identified and discussed? 
Select a Rating 




If most (six or more) of the answers to the above validity questions are “No,” the review should be designated 
with a minus (-) symbol on the Evidence Quality Worksheet. 
NEUTRAL () 
If the answer to any of the first four validity questions (1-4) is “No,” but other criteria indicate strengths, the 
review should be designated with a neutral () symbol on the Evidence  Worksheet. 
PLUS/POSITIVE (+) 
If most of the answers to the above validity questions are “Yes” (must include criteria 1, 2, 3, and 4), the report 
should be designated with a plus symbol (+) on the Evidence Worksheet. 



















































Purpose Population Intervention Key Outcomes Conclusions Limitations 























met Rome III 
criteria for 
IBS of any 


















Patients in low-FODMAP 
group had a signficant 
decrease in symptom 
scores (28%) utilizing 
IBS-SSS tool; patients on 
high-FODMAP diet had 
an increase in symptoms 
(7% increase, although 
not significant). Increases 
in dietary FODMAPs 
positively correlated with 
increasing symptoms. 
The lactulose breath test 
was not found to be a 
good predictor of diet 
responders.  
FODMAP content 
is linked to IBS 









in gut microbiota 






at the microbial 
level. 




Adequacy of the 
blinding of 





deduced the nature 
of the diet they 
were on. 






To compare the 
effect of low 
FODMAP diet 
vs "general diet 
advice" on 
quality of life 
and symptoms 




referred to GI 













Diet B: general 
IBS diet advice 
Total scores of IBS-SSS, 
scores for individual item 
symptoms, and bowel 
habit status scores 
(Bristol scale) were 
reduced in both groups; 
individual item symptoms 
& bowel habit status 
scores improved 





advice in IBS-D 
patients led to 
improvement of GI 
symptoms; low-
FODMAP diet has 







blinded only; food 
intake not 


















To assess the 


























The dietary interventions 
resulted in similar rates of 
"adequate relief" for IBS-
D symptoms (52% low 
FODMAP vs 41% NICE 
guidelines); no significant 
difference as well in 
proportion of composite 
end point responders; 
however, low-FODMAP 
diet resulted in 
significantly greater 
reductions in average 
daily scores of abdominal 
pain, bloating, 
consistency, frequency, 
and urgency as compared 
to the NICE diet. 
Both interventions 
led to adequate 
relief of overall 
symptoms in 40-
50% of patients 
with IBS-D; the 
low-FODMAP diet 
led to significantly 
greater benefit 
particularly for 
abdominal pain and 
bloating, thus 
supporting a role 






clinical benefit -- 
authors indicate 
likelihood of Type 
II error for their 
primary endpoint 
of "adequate 
relief"; food not 
provided to 
subjects; possible 
for bias to be 
introduced through 
patient deducing 
diet type or 
dietitian giving 
education. 






To compare the 


























IBS symptom severity 
reduced in both groups; 
the change in IBS-SSS 
relative to baseline did 
not differ between 
groups; a similar 
proportion of patients 
were defined as 
"responders" in both the 
treatment groups (~50% 
in each group). 
Dietary advice 
provided to 
patients with IBS 
in the clinical 
setting reduces 
symptoms but there 
are not obvious 
differences 
between a low-
FODMAP vs. a 
traditional IBS diet 
Possible that 
supplements/probi
otic intake could 
have confounded 
results (these were 












education; it seems 
possible that 
dietary advice can 
produce desired 
effects (per food 
diaries); 
calorie/nutrient 








analyzing the data 
were blinded. 






To compare GI 
symptoms over 





intake (on a 
typical 
Australian diet) 
in patients with 
IBS who had 
never had 
advice from a 
dietitian. 
Patients with 







Almost all daily 
food (3 meals & 
3 snacks) was 
provided to 





followed by the 
other 21-day 
treatment. Diets 










Overall GI symptoms 
were significantly less on 
the low-FODMAP diet 
and greater on the typical 
Australian diet, compared 
with baseline (measured 
via VAS scale). Bloating, 
pain and flatulence was 
also significantly 
improved on the low-
FODMAP diet. Patients 
of all IBS subtypes had 
greater satisfaction with 
stool consistency 
although IBS-D subjects 
were the only subtype 
with altered fecal 
frequency and King's 
Stool Chart scores. 
The low-FODMAP 
diet is effective to 
treat functional GI 
symptoms of IBS 
with symptoms 
being halved as 
compared to a 
typical Australian 
diet. This study 
supports the notion 
that the low-
FODMAP diet 
works in the vast 
majority of IBS 
patients. 
Oligosaccharide 












blinding related to 
the influence of 
change in 
symptoms; gluten 
could not be 
matched in diets--











efficacy of a 
low-FODMAP 
diet as 





















instructed by a 
dietitian to either 
eat a low-
FODMAP diet 
or a specific 
carbohydrate 





FODMAP diet had 
significant improvement 
in bloating and distention, 
while the SCD diet had a 
low & not significant 
improvement; 
comparable severity was 
shown in symptoms 
between 2 groups but a 
difference in symptoms 
after 12 days; low-
FODMAP diet did not 
cause Vit D & folic acid 
deficiencies after 3 
months. 
IBS subjects 
benefitted from a 
low-FODMAP diet 





does not seem to 
cause folic acid & 
vit D deficiencies. 
No mention of 
assessment of 
blinding; not 










mention made of 















































Lower concentrations and 
proportions of 
bifidobacteria in 
intervention group vs. 
control at follow-up; 
more patients  reported 
adequate symptom 
control in intervention 
group vs. control group 
(ITT: 68% vs. 23%); 
more patients in 
intervention group 
experienced reduction in 
bloating, borborygmi, 
urgency, and overall 
symptoms & also more 
had lower incidence of 
bloating, pain, and overall 
symptoms; intervention 
Low-FODMAP 
diet is an effective 
management 





However it can 






effects on health 
are unknown. 
No blinding 
utilized; no control 
for placebo 
response in control 
group; results 
NOT generalizable 
to IBS-C as this 




group reported lower 
stool frequency & greater 











the effect of the 
low FODMAP 
diet compared 
with a placebo 




































designed to be 
similar to low-




duration & for 
similar nutrient 
intake and fiber. 
For the ITT analysis, 
higher proportion 
reporting adequate 
symptom relief for low-
FODMAP diet, although 
did not reach significance 
like the per protocol 
analysis showed (61% 
low-FODMAP diet, 39% 
sham diet).  IBS-SSS 




abundance lower in fecal 
samples of those on low-
FODMAP diet, but 
higher in patients given 
probiotic than those given 
placebo. 
Low-FODMAP 
diet advice leads to 
improvement in 
overall and specific 
GI symptoms in 
IBS (2-3 greater 











intact (no mention 
of assessment of 







that could have 
changed (gluten, 
etc.); dichotomous 
endpoint may not 
be best primary 
outcome given 
disparity between 










To determine if 
low-FODMAP 
rye bread 
















asked to follow 
usual diet; 
provided with 
and asked to 
consume both 
low-FODMAP 
rye bread and 
regular rye bread 
As compared to the 
regular rye bread, the 
low-FODMAP rye bread 







bread caused less 




less cramps, less 
stomach rumbling 




to measure total 
FODMAPs in diet; 
NOT generalizable 
to IBS-C patients. 
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in Finland for 4 weeks (7-8 
slices during the 
2nd-4th week). 
cramps and total score of 
symptoms as measured 
by the weekly VAS. No 
differences in IBS-SSS or 
IBS-QoL scores between 
the groups.  
bread. The low-
FODMAP bread is 
also a feasible way 
to increase fiber. 






RCT to look at 
long-term 








quality of life 
& the effect of 
FODMAP 
reduction on GI 
microbiome. 
IBS patients 






provided by a 













3 months. Group 
2 received 
intervention in 
the second three 
month period 
(no education in 
initial 3 month 
period). 
Significantly lower IBS-
SSS score & increased 
QOL score in group I 
(low-FODMAP) vs. 
group II (control) at 3 
months; the reduced IBS-
SSS was sustained at 6 
months in group I (after 
reintroduction of 
FODMAPs) & replicated 
in group II. Fiber intake 
significantly decreased on 
low-FODMAP diet but 
increased again after 
reintroduction. No change 




A reduction in 
FODMAPs 
improves 
symptoms of IBS 
& the improvement 









for IBS-C so 
results not 
generalizable to 
this group; no 
blinding used so 
bias may be 
cofounding factor; 
the comparator 
group was not a 
true placebo group 
& were not 
expecting to get 
better over first 3 
mo.; high attrition 
rate leading to 
small sample sizes 
at the end of study. 
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the effect of a 
low-FODMAP 
diet vs. high 
fructo-
oligosaccharide
















given oral and 
written low-
FODMAP diet 
education (? If 
dietitian 
involved) to 
follow for 9 





















in all symptoms after 3 
weeks of low-FODMAP 
diet & significantly more 
subjects reported 
symptom relief in 
response to the placebo 
supplement (80%) vs. the 
FOS supplement (30%). 
Levels of IL-6 & IL-8 
decreased significantly 
with 3 week LFD, but no 
change in response to 
FOS supplement. Certain 
alterations in microbiota 
from both dietary 
interventions were 




efficacy of LFD in 
reducing GI 
symptoms in IBS-
D and IBS-M 
patients, as more 
patients reported 
symptom relief in 










levels of SCFAs 
may potentially 
have consequences 
for gut health. 
No analysis of 
nutritive content or 
FODMAP content 
of diet-- at 
beginning or end 
(potentially 
skewing results); 
only 1 FODMAP - 








FODMAP diet - 
effects then may 
not be solely due 
to diet changes; 
correlations not 
found, however, 
this analysis may 
not be reliable due 
to small sample 
size. Only IBS-D 
& IBS-M patients 
included. 
Primary Sources, Neutral Quality Rating 

















improvement in QOL 
score was significant 
greater in low-FODMAP 





QOL, anxiety and 
Not powered for 
this secondary 
endpoint, thus, 


















proportion of patients 
with "meaningful clinical 
response" in QOL score 
was greater in the low-
FODMAP group; anxiety 
scores decreased in low-
FODMAP group vs. 
mNICE group; activity 
impairment was 
significantly reduced with 
low-FODMAP group vs. 
mNICE group. 
activity impairment 






symptoms for IBS 
patients. 
endpoints were 





possible; limited to 
IBS-D patients. 






















either a low- or 
high-FODMAP 
diet with diets 
matched for total 
energy, total 
starch, protein, 
fat, total dietary 
fiber and 
resistant starch. 
Composite IBS symptom 
score (using Likert scale) 
significantly worse for 
IBS patients during the 
high-FODMAP diet (also 
worse for healthy subjects 
due to increased flatus) 
after 2 days; upper GI 
symptoms and lethargy 









and in IBS patients 






Very short (2 
days) and small 
study; did not 





was not a control 
or placebo group; 
? control for 
gluten content of 
food provided. 






the effects of a 
Low-FODMAP 









of any subtype 
in Denmark 
Patients 








group given 1 
hour education + 
Significant reduction of 
IBS-SSS in all patients 
during intervention & in 
each treatment group; 
signficant reduction in 
IBS-SSS observed in 
LFD & LGG groups 
compared to control 
group when comparing 
mean score at week 6; a 
significant reduction in 
Both the low-






in the IBS-D & 
IBS-A subtypes. 
No blinding; no 
placebo; no 
measure of 
adherence to the 
diet & no 
background 




group had more 
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in IBS; to 
evaluate 








foods during the 
6-week study 
period; LGG 
group told to 
follow 
unchanged diet; 







IBS-SSS found in 
patients with IBS-D & 
IBS-A (mixed or 
alternating) when treated 










To examine the 


































phase that lasted 
12 weeks. 
No statistically signficant 
difference found between 
intervention groups in 
IBS-SSS score, at either 
12 or 24 weeks; within-
group comparisons 
showed significant effects 
for both yoga and low-
FODMAP diet at both 12 
and 24 weeks; 
comparable within-group 
effects occurred for other 
outcomes. 
Both hatha yoga 
and a low-
FODMAP diet can 
reduce GI 
symptoms and 




in IBS patients; 
both treatments 
seem to be 






Inability to blind 
patients to 
interventions; lack 





















To assess the 
long-term 




















dary care in 


















months after the 
short-term 
follow-up. 
At short-term follow-up, 
61% of patients reported 
satisfactory symptom 
relief, with 57% reporting 
relief at long-term follow-
up (70% of patients 
MAINTAINED their 
relief long-term); 82% 
continued to follow 
"adapted FODMAP" diet 
while 18% returned to 
their "habitual" diet -- no 
significant differences in 
this group for 
energy/nutrient intake, 
except folate & Vit A 
were higher in "adopted 
FODMAP" group; no 
differences in food-
related QOL between 
groups; no differences for 
healthcare utilization or 
absenteeism; significantly 
more patients in the 
"adapted FODMAP" 
group ceased medication 
at long-term follow-up. 
The low-FODMAP 
diet is clinically 




FODMAP diet can 
be nurtitionally 
adequate up to 18 
months after initial 
education & 
patients find the 
diet acceptable. It 
does not adversely 
impact food-related 
QOL. 
Only 27% of 
sample responded 



















IBS via a 
prospective 
IBS patients 









ne breath testing 
performed on 3 






Mean follow-up of 15.7 
months. There was a 
significant positive 
change in almost all 
reported symptoms 
between baseline and 
follow-up, even when 
repeating the analysis 
with non-repliers 
The Low-
FODMAP diet is 
effective in 
improving 
symptoms in IBS 
patients, and those 
with fructose 
malabsorption are 
most likely to 
Observational 
study with no 
placebo control; 
response rate was 
only 46.9%, which 
may reduce 
generalization of 
results; no control 

















initial visit and 
follow-up visit 
after 6 weeks 










safety & efficacy 
of the diet.  
included; patients with 
fructose malabsorption 
were more likely to report 
improvement with certain 
symptoms than those 
without evidence of 
fructose malabsorption; 
most patients described 
ongoing adherence to the 




improvement in bloating, 
pain, flatulence, diarrhea, 
constipation, and energy 
levels. 
benefit. Current 
strategy of diet 
advice by trained 
dietitians following 
breath testing 
provides good base 
for patients to 
understand and 












diet to standard 
NICE 
guidelines as 
diet therapy for 







service in UK) 
with any 
subtype of 
IBS and that 
returned for a 
follow-up visit 
NICE general 
diet advice (and 
where indicated, 
specific NICE-










More patients in low-
FODMAP group reported 
satisfaction with their 
symptom response (76%) 
as compared to standard 
group (54%); composite 
symptom scores showed 
better response in the 
low-FODMAP group; 
significantly more 
patients in the low-
FODMAP group reported 
decreased bloating, 
abdominal pain, and 
flatulence. 
A low-FODMAP 
diet appears to be 
more effective than 
standard diet 
advice in reducing 
symptoms of IBS. 
Group 
interventions not 

















Purpose Population Intervention Key Outcomes Conclusions Limitations 
Review Articles, Positive Quality Rating 




the evidence of 
efficacy of the 
low-FODMAP 













ratios & 95% CI 
calculated for 
the effect of 
LFD on IBS-
SSS, IBS-QOL 




In RCTs, greatest 
improvement was seen 
for abdominal pain and 
bloating & low-
FODMAP diet showed 
greatest benefit in relief 
of GI symptoms; in non-
randomized interventions, 
greatest improvement 
seen in bloating, then 
flatulence, pain, diarrhea, 
nausea and constipation, 
respectively. Pooled ORs 
in both study types 
showed positive 
association between low-
FODMAP diet and 
significant decrease in 
IBS-SSS score. Both 
study types also showed 
significant improvement 












and quality of life 
scores compared to 
IBS patients 
following a normal 
diet. 
 































diet in treating 
function GI 
symptoms in 
9 articles on 
RCTs with a 







with 95% CI 
were calculated 





FODMAP diet compared 
with any control for GI 
symptoms and abdominal 
pain; low-FODMAP diet 
also had short-term 
Significant 
evidence for short-
term benefits of 
low-FODMAP diet 
on GI symptoms, 
abdominal pain, 
and quality of life 
Improvements 
were investigated 
mostly for patients 
















LFD to other 
diets and impact 




rated scale). As 
secondary 
outcomes, 
safety, quality of 
life, anxiety, 
depression, and 
effect on gut 
microbiota were 
also analyzed. 
favorable effects on 
health-related quality of 
life, as compared to 
control; none adverse 
events related to 
intervention were found. 
in IBS patients, 
with no side effects 
reported. Effects 






cultures outside of 
geographic regions 
studied & may not 
be fully applicable 
to male patients. 
Risk of bias in 
included studies 
unclear; general 
high risk of the 
studies found for 
performance bias. 
 
Altobelli et. al, 
2017, Meta-
analysis 




diets in RCTs, 
2) low- and 
high-FODMAP 
diets in RCTs, 
and 3) baseline 
vs. post-
intervention 












diet), 6 cohort 
studies. 
Odds ratios  with 
95% CI used as 
a measure of 














A low-FODMAP diet vs. 
a traditional IBS diet 
significantly reduced 
abdominal pain, bloating, 
and stool frequency (not 
stool consistency); 
significant reductions in 
pain and bloating also 
found in low-FODMAP 
diet vs. medium or high-
FODMAP diet; cohort 
studies also demonstrated 
a significant reduction in 
pain and bloating with a 
low-FODMAP diet. 
There is evidence 
that a low-
FODMAP diet can 
have a favorable 





research needs to 
be done to 
demonstrate 
whether a low-
FODMAP diet is 
superior to 
conventional IBS 




number of primary 
studies; lack of 








Varju et. al, 
2017, meta-
analysis 

















 7 controlled 

















group had to use 
standard IBS 







When comparing pre- and 
post-intervention scores 
between the control and 
low-FODMAP groups in 
the controlled trials, no 
statistically significant 
difference in pre-values 
between groups but 
significant difference in 
post-values, indicating 
low-FODMAP diet is 
better than control in 
improving IBS-SSS 
score. Significant 






quality of life in 
patients with IBS. 
A low-FODMAP 





Standard IBS diet 
group NOT 
homogeneous and 








authors for further 
info?; lack of data 
between IBS 
subtypes and in 
individual 
symptom 
improvement. 
 
 
